Main Menu

A hybridoma cell line producing a monoclonal hamster antibody specific to mouse CD69 (early activation marker) (clone H1.2F3) as described in J Immunol. 1988 Jul 15;141(2):369-76 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.

A hybridoma cell line producing a monoclonal rat antibody specific to mouse Ly-6A/E (Sca-1) (clone D7) as described in J Immunol. 1986 Nov 15;137(10):3240-6 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.

A hybridoma cell line producing a monoclonal rat antibody specific to mouse CD90 (Thy-1) (clone G7) as described in J Exp Med. 1984 Mar 1;159(3):716-30 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.

A hybridoma cell line producing a monoclonal hamster antibody specific to mouse CD51 (vitronectin receptor, alpha chain) (clone H9.2B8) as described in J Exp Med. 1989 Jun 1;169(6):2173-90 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.

NIAID has a hybridoma available for non-exclusive licensing that produces a monoclonal antibody specific for DNA/RNA hybrids. This antibody, which has been extensively characterized by NIH researchers, is already a widely-used research tool. It is currently the only monoclonal antibody available that is specific for DNA/RNA hybrids, making it a unique reagent. It is used in immuno-fluorescence (IF) microscopy, where it can be used to detect sites of transcriptional activity and potentially sites of viral replication.

The technology relates to a protein-based nanoparticle platform that allows presentation of immunogenic molecules such as influenza virus antigens. This protein platform is made up of hepatitis B capsid/core proteins. The core proteins contain immunogenic loop c/e1, where other antigens can be inserted and the chimeric protein retains the ability to form capsid-like particles. The technology describes the insertion of one or more copies of influenza epitopes derived from the globular head or the stem region of hemagglutinin protein into or around the c/e1 loop of the core protein.

Coronaviruses (CoVs) can cause severe respiratory disease with high fatality rates in humans. The 2002-2003 SARS-CoV epidemic resulted in 8098 cases and 744 deaths, and MERS-CoV, which emerged in 2012, has resulted in 2144 cases and over 750 deaths as of March 2018. Currently, there are no effective prophylactic or therapeutic measures, and because other CoVs are poised to emerge as new human pathogens, there is a need to define a general CoV vaccine solution.

Anthrax toxin proteins available for licensing. Bacillus anthracis hosts containing plasmids expressing the following proteins are available. (Host strains are generally BH480, or sometimes BH460. Modest amounts of purified proteins (10-50 mg) could also be provided):

1. PA.

Details for this material are provided in the NIH AIDS Reagent Program Catalog (Catalog# 341): https://www.aidsreagent.org/reagentdetail.cfm?t=cell_lines&id=152.

Expression, purification, and validation of anthrax toxin proteins.